

Konstantynów Łódzki, 28 January 2022.

## **Mabion joins the Great Orchestra of Christmas Charity (WOŚP) and donates headquarters visit for auction at 30th Grand Finale**

**The winner of the auction will have a chance to visit the company's laboratories and the manufacturing area where the antigen for the Nuvaxovid vaccine is produced. Mabion, a partner of the U.S. company Novavax, is the first and only Polish company to be directly involved in the production process of the COVID-19 vaccine. All proceeds from the auction will be transferred to the account of the 30th Grand Finale of the Great Orchestra of Christmas Charity.**

Winning the auction is the only chance to visit the company's headquarters, which is normally only accessible to its employees, just like other such facilities. This time, given the charitable cause of the initiative, Mabion is opening its doors not only to the winner himself, but also to three accompanying persons of their choice. Luckily, a biotechnology degree is not necessary.

*This is a truly unique opportunity to get to know our company, take a look at the production process of recombinant proteins and experience biotechnology in practice through the experiments we have prepared for our guests. We would like to invite anyone who would like to make a contribution to the 30th Grand Finale of the Great Orchestra of Christmas Charity and at the same time deepen their understanding of this sector to take part in the auction. One of our tasks as a company is to build a national economy based on knowledge, using the potential of Polish scientists. Now we would like to share at least some of this knowledge, - says **dr. inż. Sławomir Jaros, Mabion S.A. board member for scientific and operational affairs.** It will be possible to discuss vaccines, recombinant protein technology, but also the people who create this unique project, with dr. Jaros as part of the first item on the day's agenda.*

After the theoretical introduction, there will be time for practical activities and getting to know the capabilities of the company's research and development laboratories. It is there that visitors will be able to conduct cell bank experiments on their own, although still under the watchful eye of Mabion employees, such as starting a culture or viewing cells under a microscope. The next item on the agenda is exploring the world of analytics. Again, with the support of experts and using the latest technology, the winner of the auction and companions will carry out the processes of analysing biological drug samples, along with processing the data obtained and obtaining the result. After the challenges under laboratory conditions, it will be time to explore with production. This will involve a tour of the manufacturing area, which is where the antigen for the Nuvaxovid vaccine is produced. Due to the

restrictions caused by the pandemic, the walk through this part of the plant will be virtual. Throughout the visit, the company's specialists will answer all the visitors' questions comprehensively and in simple, understandable words - both the basic ones, e.g. what is an antigen, and more advanced ones, such as details of the technology transfer process needed to produce the very antigen. The knowledge gained always looks better with a certificate, which is why the last item of the tour is obtaining an "Honorary Mabion Biotechnologist" diploma.

The auction is conducted in cooperation with the headquarters of the 30th Grand Finale of the Great Orchestra of Christmas Charity at the Medical University of Łódź. Due to safety requirements, only adults are invited to participate. Auction of a visit to the plant is just one of the ways in which Mabion supports WOŚP. An e-wallet has also been launched, which employees can fund online, and for willing people who prefer traditional forms of support, two Mabion's offices (in Łódź and Konstancin-Jeziorna) were equipped with donation boxes. Apart from regular support for the Great Orchestra of Christmas Charity, collections among employees were also organised in previous years. The company is involved in helping the local community on a daily basis. Mabion financially supports hospices and orphanages in Łódź and regularly organises events aimed at raising environmental awareness. It has received an award from the Mayor of Łódź for its activities.

#### **Key items of the "Day at Mabion" event auction:**

- \* maximum duration: 8 hours,
- \* location: Mabion, ul. Langiewicza 60, Konstancin-Jeziorna,
- \* number of visitors: 4,
- \* lecture and discussion on vaccines with a member of the board of scientific and operational affairs dr. inż Sławomir Jaros,
- \* introduction to manufacturing protein products on a commercial scale,
- \* experimental work - cell culture part: introduction to sterile work, starting a cell bank culture, observing cells under a microscope, using a cell counter. The cell culture started will be carried on and after a few days pictures from the cell counter will be available,
- \* experimental work - biochemical part: introduction to liquid chromatography and mass spectrometry, conducting an experiment using the UHPLC system, including processing the data obtained and providing the result,
- \* tour of the manufacturing area (virtual or live, depending on the date),
- \* certification: receiving the diploma of "Honorary Mabion Biotechnologist".

#### **Information about Mabion S.A.**

Mabion S.A. (WSE: MAB) is a fully integrated Polish biopharmaceutical company established in 2007 whose core business is the design and development of the latest generation of medicines based on recombinant protein technology (e.g., monoclonal antibodies). Mabion's competencies cover both the drug design phase and the selection of protein expression technologies, their purification, production activities in the GMP standard (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), the development of analytical tools (for structural, functional, physicochemical characterization), clinical

development, clinical analytics and a full range of regulatory activities in the development and operational areas. The company's most advanced project is MabionCD20, a biosimilar to MabThera (rituximab) with therapeutic indications for non-Hodgkin lymphoma, leukaemia and rheumatoid arthritis (RA). In addition, since signing the contract with Novavax in October 2021 for the commercial production of the vaccine for COVID-19, Mabion has been developing and expanding its existing platform to include CDMO activities, i.e. contract development services, GMP manufacturing and GMP/GLP analytical services across the full range of the above capabilities. Mabion is a public company listed on the Warsaw Stock Exchange. For more information about the Company, please visit [www.mabion](http://www.mabion)